Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy

Seminars in Oncology

Volumn 39, Issue 3, 2012, Pages 305-310

  Osada, Takuya ^a   Morse, Michael A ^a   Hobeika, Amy ^a   Lyerly Kim, H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOVIRUS VECTOR; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; MANNOSE RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR;

ALPHA VIRUS; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; COMPLEMENT DEPENDENT CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REPLICON; SIGNAL TRANSDUCTION;

ADENOVIRIDAE; ALPHAVIRUS; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, SYNTHETIC;

EID: 84861108589     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.013     Document Type: Article

References (22)

1. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
2. M.A. Morse, R. Chapman, J. Powderly Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self antigens in cancer patients Clin Cancer Res 17 2011 4844 4853
3. J.L. Marshall, R.J. Hoyer, M.A. Toomey Phase I study in advanced cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses J Clin Oncol 18 2000 3964 3973
4. S.P. Buchbinder, D.V. Mehrotra, A. Duerr Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial Lancet 372 2008 1881 1893
5. R.M. Paris, J.H. Kim, M.L. Robb, N.L. Michael Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1 Expert Rev Vaccines 9 2010 1055 1069
6. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
7. J.L. Marshall, J.L. Gulley, P.M. Arlen Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas J Clin Oncol 23 2005 720 731 (Pubitemid 46224171)
8. P. Pushko, M. Parker, G.V. Ludwig, N.L. Davis, R.E. Johnston, J.F. Smith Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo Virology 239 1997 389 401 (Pubitemid 28105644)
9. G.H. MacDonald, R.E. Johnston Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis J Virol 74 2000 914 922 (Pubitemid 30036228)
10. M.A. Morse, A.C. Hobeika, T. Osada An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer J Clin Invest 120 2010 3234 3241
11. P. Gallo, S. Dharmapuri, B. Cipriani, P. Monaci Adenovirus as vehicle for anticancer genetic immunotherapy Gene Ther 12 Suppl 1 2005 S84 S91
12. K. McCoy, N. Tatsis, B. Korioth-Schmitz Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors J Virol 81 2007 6594 6604 (Pubitemid 46878063)
13. P. Abbink, A.A. Lemckert, B.A. Ewald Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D J. Virol 81 2007 4654 4663 (Pubitemid 46668663)
14. J.W. Schoggins, E. Falck-Pedersen Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity J Virol 80 2006 10634 10644 (Pubitemid 44628909)
15. S.S. Seregin, A. Amalfitano Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors Expert Opin Biol Ther 9 2009 1521 1531
16. T. Osada, X.Y. Yang, Z.C. Hartman Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity Cancer Gene Ther 16 2009 673 682
17. E.S. Gabitzsch, Y. Xu, L.H. Yoshida Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity Vaccine 27 2009 6394 6398
18. E.S. Gabitzsch, Y. Xu, L.H. Yoshida A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-]recombinant-based vaccine used to induce cell mediated immune responses Immunol Lett 122 2009 44 51
19. E.S. Gabitzsch, Y. Xu, J.P. Balint Jr, Z.C. Hartman, H.K. Lyerly, F.R. Jones Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA Cancer Immunol Immunother 59 2010 1131 1135
20. Osada T, Berglund P, Morse MA, et al. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunol Immunother. In press.
21. Z.C. Hartman, T. Osada, O. Glass Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity Cancer Res 70 2010 7209 7220
22. R.J. Barth Jr, D.A. Fischer, P.K. Wallace A randomized trial of ex vivo CD40L activation of a DC vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival Clin Cancer Res 16 2010 5548 5556